Biotech stocks have stalled in 2016 along with the broader markets, with the iShares Nasdaq Biotech ETF (Nasdaq: IBB) down 24.43% year to date.
Still, Money Morning Biotech Investing Specialist Ernie Tremblay says the sector will outperform in 2016. And he's pinpointed one foundational play that's already climbed 14% in the last five days.
But first, here's why biotech stocks are presenting a huge opportunity right now...
With a net worth of $12.6 billion, Patrick Soon-Shiong, MD, is the world's richest doctor, the richest American in the healthcare industry, and the 96th-richest person on the planet in 2015 according to Forbes.
And just in August, the 63-year-old became $1.1 billion richer -- from a move he'd made only eight months prior, according to Bloomberg...
Here's Soon-Shiong's story - plus five ways you can cash in with biotech profits of your own...
Start the conversation
Leave a Reply
Today, we're recommending a biotech stock to buy that Money Morning Biotech Investing Specialist Ernie Tremblay says has a "nearly limitless" profit potential.
It's a medical device company with a revolutionary product that helps restore vision to people suffering from blindness.
Here's the revolutionary technology behind this biotech stock to buy...
Start the conversation
Leave a Reply
Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has dipped nearly 5% in the last week after the company reported a Q2 earnings loss of $0.80. Analysts had been predicting a loss of $0.75 for the quarter.
In the past three months, TRIL stock has now dipped 16.4%, and the poor earnings report only stoked the fears of nervous investors.
Investors who know how to choose the best biotech stocks to buy can cash in. In the last twelve months alone, the Nasdaq Biotechnology Index ETF has outperformed the broader Nasdaq Composite by 25.5%. And the SPDR S&P Biotech ETF has outperformed the S&P 500 almost sevenfold.
Watch our three-minute video for five easy steps to picking the best biotech stocks to buy...
Start the conversation
Leave a Reply
One of the last week's biggest IPOs, the food allergy company Aimmune Therapeutics Inc. (Nasdaq: AIMT), hit the market on Thursday, Aug. 6, and has already climbed more than 20%.
AIMT's early success underscores one of the best biotech stocks to buy that Money Morning Executive Editor Bill Patalon has been recommending all year.
Trillium Therapeutics Inc. (Nasdaq: TRIL) stock has climbed 143% in 2015, and it's still one of the top biotech stocks to buy now.
You see, Trillium is at the forefront of a revolutionary treatment that could hold the key to curing various types of cancer.
Spending on cancer treatment has been skyrocketing globally. According to the IMS Institute of Health, spending on cancer topped $100 billion globally in 2014. That was a 10% increase from 2013.
That's why many biotech stocks tied to cancer treatments have seen triple-digit gains in the last two years.
On Jan. 7, 2015, CytRX Corp. announced positive results from a study of its experimental brain cancer drug, aldoxorubicin, and the company's stock immediately jumped 15.8%. Then, over the next four months, it nearly doubled.
Over the months since June 2013, when Clovis Oncology released positive trial data for both a lung cancer and a lymphoma drug, CLVS share value has soared 255%.
And just last summer, when Puma Biotechnology released positive results from a clinical trial of its breast cancer drug, neratanib, PBYI shares jumped 300% in a single session.
It's clear that investors can do very well with the right cancer drug.
But there, of course, is the rub: Finding the right cancer drug is not so easy.
Start the conversation
Leave a Reply
Biotech stocks have seriously outperformed the markets in 2015, and our favorite biotech ETF has been one of the biggest winners.
In the last year, the Nasdaq Biotechnology Index has soared 48.3%. The Dow and S&P 500 are up just 7.3% and 8.6% in that time.
Here's our favorite biotech ETF to buy now...
Start the conversation
Leave a Reply
Organovo Holdings Inc. (NYSE: ONVO) stock is up 12.7% this week after the company reported quarterly and fiscal year earnings on Tuesday.
For the quarter ending March 31, ONVO reported an earnings per share (EPS) loss of $0.10. That was below the consensus estimate of a $0.09 loss.
Here's what else investors need to know about ONVO stock now...
Start the conversation
Leave a Reply
One of our favorite biotech stocks of 2015, Organovo stock, has climbed 41% since the end of March. And that's just the start for this revolutionary biotech investment.
You see, Organovo Holdings Inc. (NYSEMKT: ONVO) is part of one of the most exciting biotech industries on the market. It's called 3D bioprinting, and the applications are huge.
Start the conversation
Leave a Reply
Global cancer spending topped $100 billion for the first time after climbing a whopping 10% in 2014.
And that's a major "buy" signal for one of the top biotech stock picks we've been recommending at Money Morning.
According to a report from the IMS Institute of Health, rising drug prices and increased incidence of cancer led to the 10% spike in drug spending last year.
Here's what that means for our top investment...
Start the conversation
Leave a Reply
The biotech market has sold off last week, with the Nasdaq Biotechnology Index dropping 6.4% since April 23. And because of that, some of the best biotech stocks have dipped as well.
Now, investors are wondering if they should take their money to the sideline. But Money Morning's Bioscience Investing specialist Ernie Tremblay says this type of move is normal for the biotech market.
Here are three stocks we're recommending now that they're trading at discounted prices...
Start the conversation
Leave a Reply
Gilead Sciences Inc. (Nasdaq: GILD) is facing criticism again this week for its highly priced Hepatitis C drug Sovaldi. The drug costs $1,000 per pill.
According to The Wall Street Journal, many states have restricted access to the drug, leaving some patients unable to afford the treatment.
Start the conversation
Leave a Reply
If you're looking for the best biotech stocks on the market, you've come to the right place.
Our biotech specialists aren't considered to be among the best... they are the best.
And they picked three of the best biotech stocks to profit from today...
Start the conversation